Global Infectious Disease Diagnostics Testing Market Outlook 2025-2034: Trends, Innovations, And Future Outlook

The Infectious Disease Diagnostics Testing Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Infectious Disease Diagnostics Testing Market Size and Projected Growth Rate?
The infectious disease diagnostics testing market size has grown rapidly in recent years. It will grow from $38.52 billion in 2024 to $42.56 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to rising disease outbreaks such as SARS, Ebola, and Zika, growing awareness among healthcare professionals and the general public about the importance of early detection and prevention of infectious diseases, rise in government-funded programs for disease surveillance, control, and prevention, increasing global travel and trade have facilitated the spread of infectious diseases, and increased healthcare spending, particularly in emerging economies.

The market for infectious disease diagnostics testing is anticipated to experience rapid expansion in the upcoming years, expected to reach $62.58 billion by 2029 with a compound annual growth rate (CAGR) of 10.1%. This growth is primarily driven by the continuous emergence of new pathogens, such as novel strains of influenza and COVID-19, the shift towards personalized medicine and targeted treatments, the increasing demand for rapid and on-site testing solutions, heightened focus on epidemiological surveillance and early detection systems, and growing investments in research and development aimed at creating innovative diagnostic technologies and biomarkers. Key trends during this period will include miniaturization and portability of diagnostic devices, the adoption of multiplex assays that can detect multiple pathogens at once, the integration of digital health technologies like mobile apps and telemedicine platforms, the incorporation of next-generation sequencing (NGS) technologies, advancements in biosensors for rapid and accurate detection, and the use of AI and machine learning algorithms in diagnostic platforms.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15831

What Are the Major Segments in the Infectious Disease Diagnostics Testing Market?
The infectious disease diagnostics testing market covered in this report is segmented -

1) By Type: Molecular Diagnostic Test, Point Of Care Tests (POCT) Infectious Disease Diagnostics Test
2) By Application: Respiratory, Human Immunodeficiency Virus (HIV), Healthcare-Associated Infections (HAIs), Sexual Health, Tropical Diseases, Liver
3) By End-User: Diagnostic Laboratories, Hospitals And Clinics, Academic Research Institutes, Other End-Users

Subsegments:
1) By Molecular Diagnostic Test: Polymerase Chain Reaction (PCR) Tests, Nucleic Acid Amplification Tests (NAATs), Next-Generation Sequencing (NGS), Microarray-Based Tests
2) By Point Of Care Tests (POCT) Infectious Disease Diagnostics Test: Lateral Flow Assays, Rapid Antigen Tests, Immunoassays, Portable PCR

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15831&type=smp

What Are The Driving Infectious Disease Diagnostics Testing Market Evolution?
A rise in respiratory infections is set to support the infectious disease diagnostic testing market. These infections impact the lungs, airways, throat, and nasal passages, and are increasing due to viral and bacterial spread, close living environments, poor hygiene, and seasonal changes. Diagnostic testing plays a critical role in identifying these diseases accurately by detecting viruses and bacteria in patient samples. For instance, in February 2024, the Canadian Institute for Health Information reported that hospitalizations for acute upper respiratory infections rose 32%, from 2,114 in 2022 to 2,797 in 2023. Therefore, rising respiratory infections are boosting the infectious disease diagnostic testing market.

Which Firms Dominate The Infectious Disease Diagnostics Testing Market Segments?
Major companies operating in the infectious disease diagnostics testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton dic*kinson And Company, Quest Diagnostics Incorporated, Grifols S.A., Hologic Inc., PerkinElmer Inc., bioMérieux SA, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., DiaSorin SpA (Luminex), Myriad Genetics Inc., Seegene Inc., Ortho Clinical Diagnostics Inc., OraSure Technologies Inc., Meridian Bioscience Inc., Trinity Biotech PLC, Biodesix Inc., Helix OpCo LLC, Inovio Pharmaceuticals Inc.

What Infectious Disease Diagnostics Testing Market Trends Are Gaining Traction Across Different Segments?
Leading firms in the infectious disease diagnostic testing market are shifting their focus towards the creation of cutting-edge technologies like molecular diagnostics platforms to maintain their market stance. These molecular diagnostics platforms are advanced systems made to identify and analyze nucleic acids (either DNA or RNA) from biological samples for diagnostic objectives. For instance, a US-based medical technology corporation known as Becton dic*kinson and Company introduced the BD COR System, a completely automated high-efficiency infectious disease molecular diagnostics platform, in May 2022. This platform seamlessly integrates and automates the full molecular laboratory procedure from sample handling to diagnostic results, removing the requirement for manual sample sorting and liberating lab specialists for more complex tasks. This system has the capacity to handle up to 1,700 samples and provide results in less than 24 hours, providing high-efficiency capabilities and sophisticated genotyping for diseases like HPV and STIs.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/infectious-disease-diagnostics-testing-global-market-report

Which Is The Largest Region In The Infectious Disease Diagnostics Testing Market?
North America was the largest region in the infectious disease diagnostics testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease diagnostics testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Infectious Disease Diagnostics Testing Market?
2. What is the CAGR expected in the Infectious Disease Diagnostics Testing Market?
3. What Are the Key Innovations Transforming the Infectious Disease Diagnostics Testing Industry?
4. Which Region Is Leading the Infectious Disease Diagnostics Testing Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.